Author Correction: PI3K inhibitors are finally coming of age

Affiliations

¹ UCL Cancer Institute, University College London, London, UK. bart.vanh@ucl.ac.uk.
² Medicinal Chemistry, Research and Early Development, Respiratory & Immunology BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
³ CLL Center, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.
⁴ Institut Gustave Roussy, INSERM U981, Université Paris Saclay, Paris, France.
⁵ Department of Pathology, University of Cambridge, Cambridge, UK.

Published Erratum

Bart Vanhaesebroeck et al. Nat Rev Drug Discov. 2021 Oct.

. 2021 Oct;20(10):798.

doi: 10.1038/s41573-021-00300-7.

¹ UCL Cancer Institute, University College London, London, UK. bart.vanh@ucl.ac.uk.
² Medicinal Chemistry, Research and Early Development, Respiratory & Immunology BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
³ CLL Center, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.
⁴ Institut Gustave Roussy, INSERM U981, Université Paris Saclay, Paris, France.
⁵ Department of Pathology, University of Cambridge, Cambridge, UK.

No abstract available

Erratum for

PI3K inhibitors are finally coming of age.
Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. Vanhaesebroeck B, et al. Nat Rev Drug Discov. 2021 Oct;20(10):741-769. doi: 10.1038/s41573-021-00209-1. Epub 2021 Jun 14. Nat Rev Drug Discov. 2021. PMID: 34127844 Free PMC article. Review.